Introduction:Upfront neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy remained a standard of care for locally advanced rectal cancers. However this strategy is associated with high rates of distant failure. Total neoadjuvant therapy with short course radiation therapy (SCRT) followed by full course of chemotherapy is investigated to assess toxicity&feasibility. Patients and methods: Fifty-one patients with locally advanced rectal cancer who presented to the National Cancer Institute (NCI), Cairo University, in the period from March 2018 to December 2020 were enrolled. Patients were assigned to neoadjuvant short course radiation therapy (25 Gy/ 5 fractions/1 week), then 2 weeks from the end of radiation they were commenced to full course chemotherapy CAPOX (capecitabine1000 mg/m2 BID, D1-14 and oxaliplatin 130 mg/m2 D1) for 6 cycles, followed by surgery within 4-6 weeks from the last chemotherapy cycle. Type of surgery was decided upon surgeon’s discretion. Results: All patients completed their planned radiation therapy. Only 1 patient had grade III radiation related diarrhea. Forty three patients completed their planned chemotherapy course, 8 patients had grade III diarrhea. As regard hematological toxicity, 6 patients developed grade 3 toxicity and only one patient developed grade 4 toxicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.